麻豆社

In response to draft text for the WTO-led waiver on IP for COVID-19 vaccines,听Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry, said:

鈥淪trong intellectual property protections underpinned the rapid development of vaccines and treatments against COVID-19. The draft proposals from the WTO completely undermine this system and seek to resolve a problem that doesn鈥檛 exist.

鈥淩ather than support the efforts already underway to get COVID-19 vaccines to people in lower- and middle-income countries, these proposals will divert attention away from workable solutions and undermine the research needed to protect us from future pandemics.鈥�

The pharmaceutical industry has increased vaccine production capacity to over 1 billion doses a month. Continuous investment in manufacturing, together with 371 licensing agreements on vaccines, meant reaching the milestone of 12 billion doses by January 2022.

Boosting equitable access to COVID-19 vaccines

Industry has also put forward its for increasing access to COVID-19 vaccines:

• Step up support for country readiness to roll out COVID-19 vaccine doses
• Contribute to equitable distribution of COVID-19 vaccine doses
• Continue to drive innovation